


November 27th, 2017

CIRM

CALIFORNIA'S STEM CELL AGENCY



Joint Transition and Science Subcommittee Meeting
Jonathan Thomas, Chairman ICOC

Goal

- To identify strategies to sustain the Agency beyond Proposition 71 funding.

Agenda

- Context
- Citizen-led bond measure in November 2020
- Allocation of remaining research dollars
- Bridge funding
- Other fundraising options/goals

Context

- At our current rate of drawdown, research funds could now run out as early as 2019.
- The goal is to raise \$222M to continue all of CIRM's programs through calendar year 2020.
- CIRM at a critical stage of its mission:
 - On track to achieve Strategic Plan goals
 - Early successes for curative therapies (Kohn SCID and XCGD)
 - Promising early returns on other fronts (Asterias)
 - Increased industry partnerships

2020 Bond Measure

- Citizen-sponsored bond measure November 2020
- Legislative option November 2020
 - Back-up option; will continue to update legislators and constitutional candidates

Research Budget Allocation


- Presentation by Dr. Maria Millan

Fundraising Scenario:

Preserves CIRM Value Proposition
Increases "Shots on Goal" & Pipeline

	2018	2019	2020
CLIN	\$130 M	\$130 M	\$114 M (8 More Trials; 4 More Late Stage Clinical Candidates)
TRAN	\$30 M	\$25 M	\$40 M (8 More TRAN Candidates)
DISC	\$10 M	\$9.25 M	\$20 M (12 Additional DISC2 Projects)
EDUC	\$750 K	\$0 K	\$16 M (5 New Training Awards)
INFR	ongoing	ongoing	\$16 M (2 New Alpha Clinics)

Maintaining Momentum and CIRM's Value Proposition



Donations can be directed to:



Supplemental Fundraising

Given recent successes in the field, donors are interested in co-funding one or many projects

- Criteria
- Will piggy back off GWG recommendations and Board approval